FLT-PET/MRI imaging for the evaluation of early response to immune checkpoint inhibitors
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000027460
- Lead Sponsor
- Third department of internal medicine, Universtiy of Fukui
- Brief Summary
This prospective study showed that changes in TLP measured by 18F-FLT PET as early as 2 weeks after treatment initiation could have utility as predictors of the response and progression-free survival of NSCLC patients treated with anti-PD-1 antibody therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
Not provided
Exclusion Criteria
1) Pregnant woman 2) Patients with metalic device in their body 3) Patients with claustrophobia 4) Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X-ray. 5) Patients with collagen vascular disease or autoimmune diseases 6) Other cases attending physician it is determined unsuitable for registration of the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relationship between serial FLT-PET/MRI findings of the tumor and progression free survival and tumor response.
- Secondary Outcome Measures
Name Time Method 1. Association of serial change of FLT-PET/MRI findings with overall survival. 2. Association of FLT-PET/MRI findings and PD-L1 expression of lung cancer.